2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-I0008
    3-(Trifluoromethyl)cinnamic acid 779-89-5 ≥98.0%
    3-(Trifluoromethyl)cinnamic acid is a cinnamic acid derivative which can be extracted from Polygalae Radix. 3-(Trifluoromethyl)cinnamic acid exerts hepatoprotective, anti-gastric lesions and anti-neurodegenerative effects and can be used in chemical synthesis .
    3-(Trifluoromethyl)cinnamic acid
  • HY-105343
    BW-180C 63631-40-3 99.92%
    BW-180C ([D-Ala2, D-Leu5]-Enkephalin; DADLE) is an δ opioid receptor (DOR) agonist, which belongs to the enkephalin family. Neuroprotective agent. BW-180C reversibly inhibits cellular transcription in neurons without causing cell injury.
    BW-180C
  • HY-163172
    Miro1 Reducer 2624336-91-8
    Miro1 Reducer is a small molecule that can repair this defect of Miro1 in Parkinson's disease (PD) fibroblasts. Miro1 Reducer reduces the delayed mitophagy phenotype in PD fibroblasts. Miro1 Reducer reduces Miro1 protein levels in dose-dependent manner (IC50 = 7.8 mM).
    Miro1 Reducer
  • HY-B0563A
    Ropivacaine hydrochloride monohydrate 132112-35-7 99.82%
    Ropivacaine hydrochloride monohydrate is a potent sodium channel blocker and blocks impulse conduction via reversible inhibition of sodium ion influx in nerve fibrese. Ropivacaine is also an inhibitor of K2P (two-pore domain potassium channel) TREK-1 with an IC50 of 402.7 μM in COS-7 cell's membrane. Ropivacaine is widely used for regional anesthesia and neuropathic pain management in vivo.
    Ropivacaine hydrochloride monohydrate
  • HY-U00228
    Rilmazafone hydrochloride 85815-37-8 99.75%
    Rilmazafone hydrochloride (450191S) is a benzodiazepine (omega) ligand.
    Rilmazafone hydrochloride
  • HY-124569
    NAB-14 1237541-73-9
    NAB-14 is a potent, selective, orally active and non-competitive GluN2C/2D antagonists with an IC50 of 580 nM for GluN1/GluN2D. NAB-14 shows >800-fold selective for recombinant GluN2C and GluN2D over GluN2A and GluN2B. NAB-14 can cross the blood-brain-barrier.
    NAB-14
  • HY-12650
    Mirogabalin 1138245-13-2 ≥98.0%
    Mirogabalin (DS-5565) is a novel, preferentially selective α2δ-1 ligand characterized by high potency and selectivity to the α2δ-1 subunit of voltage-sensitive calcium channel complexes in the CNS.
    Mirogabalin
  • HY-18976
    UF010 537672-41-6 99.84%
    UF010 is a selective inhibitor of class I HDAC. UF010 has cytotoxicity to cancer cells and reduces neuroinflammation in the hippocampus. UF010 can be used for the research of neurological diseases.
    UF010
  • HY-B0246S
    Carbamazepine-d10 132183-78-9 99.41%
    Carbamazepine-d10 is the deuterium labeled Carbamazepine. Carbamazepine (CBZ), a sodium channel blocker, is an anticonvulsant agent[1][2].
    Carbamazepine-d10
  • HY-10053
    Maropitant 147116-67-4 ≥98.0%
    Maropitant is an orally active NK1 receptor antagonist. Maropitant prevents vomiting and inhibits ulcerative dermatitis.
    Maropitant
  • HY-16639
    ML314 1448895-09-7 99.52%
    ML314 is a potent molecule agonist of NTR1 (EC50 = 1.9 μM); showed good selectivity against NTR2 and GPR35, but does not stimulate Ca2+ mobilization.
    ML314
  • HY-16716
    Basmisanil 1159600-41-5 99.91%
    Basmisanil (RG1662) is a highly selective orally active α subunit-containing GABAA receptors (GABAAα5) negative allosteric modulator (NAMs). Basmisanil can inhibit GABAA-α5 with a Ki value of 5 nM and IC50 value of 8 nM, respectively. Basmisanil can be used for the research of multiple cognitive and psychiatric disorders.
    Basmisanil
  • HY-19733
    Lumateperone tosylate 1187020-80-9 99.78%
    Lumateperone (ITI-007) tosylate is a 5-HT2A receptor antagonist (Ki = 0.54 nM), a partial agonist of presynaptic D2 receptors and an antagonist of postsynaptic D2 receptors (Ki = 32 nM), and a dopamine D1 receptor modulator. Lumateperone tosylate has anticancer activity and can also be used in studies of psychiatric disorders such as schizophrenia.
    Lumateperone tosylate
  • HY-100371
    (RS)-MCPG 146669-29-6 99.05%
    (RS)-MCPG (alpha-MCPG) is a competitive and selective group I/group II metabotropic glutamate receptor (mGluR) antagonist. (RS)-MCPG blocks theta-burst stimulation (TBS)-induced shifts in both juvenile and neonatal rat hippocampal neurons.
    (RS)-MCPG
  • HY-133130
    JNJ-42226314 1252765-13-1 99.42%
    JNJ-42226314 is a competitive, highly selective and reversible non-covalent monoacylglycerol lipase (MAGL) inhibitor. JNJ-42226314 demonstrates dose-dependent enhancement of the major endocannabinoid 2-arachidonoylglycerol (2-AG) as well as efficacy in models of neuropathic and inflammatory pain.
    JNJ-42226314
  • HY-14852A
    Tafamidis meglumine 951395-08-7 99.79%
    Tafamidis meglumine (Fx-1006A) is a potent and selective transthyretin (TTR) stabilizer, shows comparable potency and efficacy to the mutumant homotetramers V30M-TTR, V122I-TTR and wild type WT-TTR, with EC50s of 2.7-3.2 μM. Tafamidis meglumine inhibits amyloidogenesis.
    Tafamidis meglumine
  • HY-B0457A
    Clomipramine 303-49-1 99.48%
    Clomipramine (Chlorimipramine) is a potent 5-HT reuptake blocker with the IC50 value of 1.5 nM. Clomipramine is a tricyclic antidepressant that can be used for the research of depression and obsessive compulsive disorder (OCD).
    Clomipramine
  • HY-100013C
    2-PCCA hydrochloride 99.63%
    2-PCCA hydrochloride is a GPR88 receptor agonist, and inhibits GPR88-mediated cAMP production, with an EC50 of 116 nM in HEK293 cells.
    2-PCCA hydrochloride
  • HY-19863
    F-15599 635323-95-4 99.82%
    F-15599 is a highly selective G-protein biased 5-HT1A receptor agonist, with Ki of 3.4 nM.
    F-15599
  • HY-101449
    Adaptaquin 385786-48-1 99.87%
    Adaptaquin is a BBB-penetrable HIF-PHDs inhibitor. Adaptaquin has anti-inflammatory and neuroprotective effects. Adaptaquin can effectively inhibit lipid peroxidation, maintain mitochondrial function, and reduce neuronal death. Adaptaquin can be used in the research of nervous system diseases such as Parkinson's disease.
    Adaptaquin
Cat. No. Product Name / Synonyms Application Reactivity